Pubblicato il

Restorative Dentistry Market To Grow Fastest in Asia-Pacific

Restorative Dentistry Market

The total size of the restorative dentistry market was USD 15,789.2 million in 2022, and it will grow at a rate of 6.2% in the years to come, to reach USD 25,608.0 million by 2030, according to P&S Intelligence, a market research firm.

There is a considerable increase in the incidence of oral health problems globally, particularly among youngsters and the aging people recently. Caries is the most common of these conditions, missing teeth, and periodontal diseases contributing to the increasing acceptance of restorative dentistry.

Dental prosthetics will grow at a rate of about 8% in the years to come. This has a lot to do with the growing demand for dental procedures as a result of the increasing frequency of tooth decay, teeth loss, and other oral health conditions.

The implantology category dominated the restorative dentistry market, with about 50% share, in 2022, and it will grow the fastest in the years to come, due to the growing requirement for dental implants in developed nations.

Europe had the largest share of revenue of, about 45%. This is because of the increasing frequency of dental diseases, the rising geriatric population, the incidence of leading players, and the booming expenditure of the governments on dental care.

Moreover, APAC will grow the fastest because of huge patient base in India and China. Furthermore, government initiatives and the medical industry expansion are will power the market development in the near future.

Due to the growing requirement of cosmetic and dental surgeries, the demand for restorative dentistry treatments will continue to grow considerably by the end of this decade.

Pubblicato il

Asia-Pacific Expected To Witness Boom in Agricultural Biotechnology Industry in Near Future

Agricultural Biotechnology Market

The global agricultural biotechnology market had a value of $39,565.6 million in 2020, and it is predicted to advance at a CAGR of 10.7% between 2021 and 2030. Furthermore, the market will generate a revenue of $106,870.0 million by 2030, as per the estimates of the market research company, P&S Intelligence. The market is being driven by the increasing requirement for new breeding techniques such as plant grafting, plant molecular breeding, genetic engineering, and genomic sciences.

This is due to the ballooning adoption of biotechnology for creating or modifying traits of organisms-including animals, microbes, and plants with respect to size, yield, or color. Additionally, the soaring demand for food items is propelling the expansion of the agricultural biotechnology market. As per the United Nations Department of Economic and Social Affairs, the total population across the world grew from 6.9 billion in 2010 to 7.7 billion in 2019.

Moreover, half of the world’s population growth between 2015 and 2050 is predicted to be concentrated in mainly ten countries such as China, Nigeria, India, Pakistan, the U.S., the Democratic Republic of the Congo, Ethiopia, Uganda, Indonesia, and Tanzania. The surge in the global population will push up the requirement for food products, which will, in turn, fuel the usage of advanced biotechnology tools in agricultural processes, thereby driving the expansion of the market.

Depending on technology, the agricultural biotechnology market is classified into deoxyribonucleic acid (DNA) sequencing, genome editing, synthetic biology, biochip, and ribonucleic acid interference (RNAi). Out of these, the genome editing category led the market in 2020, due to the large-scale usage of genome tools in farming processes and extensive genome research activities. Furthermore, when product is taken into consideration, the market is divided into crop protection products and transgenic seeds.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/agricultural-biotechnology-market/report-sample

Out of these, the crop protection products category is predicted to demonstrate the higher growth rate in the market in the coming years. This is credited to the rapid technological advancements being made in the domain of agricultural chemistry that have allowed farmers to focus heavily on effective pest management. The growing public awareness about biopesticides is fueling their adoption and also raising awareness about organic farming, which is, turn propelling the advancement of the category.

Globally, the agricultural biotechnology market is predicted to demonstrate the fastest growth in the Asia-Pacific (APAC) region in the forthcoming years. This is attributed to the fact that the APAC region offers several opportunities for genetically modified (GM) crop production, due to the surging adoption of advanced farming practices for enhancing productivity. Moreover, the developing nations of APAC are prioritizing mechanization for raising the yield and productivity of farmlands. This is positively impacting the market expansion in this region.

Hence, it can be said with confidence that the market will register huge expansion in the coming years, primarily because of the ballooning requirement for food products and higher agricultural productivity, on account of the surging population all over the world.

Pubblicato il

Wearable Medical Devices Industry Growth, Development and Future Scope

Wearable Medical Devices Market

The World Obesity Federation predicts that over 1 billion people will be affected by obesity and nearly 2.7 billion adults will be overweight by 2025. The surging prevalence of obesity is creating extensive awareness among the masses regarding health and fitness. Additionally, private and public organizations are organizing numerous seminars and programs to raise public awareness about health and fitness. Moreover, medical device manufacturing companies are also offering dietician- and nutritionist-backed tips, suggestions, and advice to encourage the usage of wearable medical devices.

Thus, the rising fitness consciousness will help the wearable medical devices market advance at an exceptional CAGR of 18.3% during 2020–2030. The market was valued at $10.6 billion in 2019 and it is projected to generate $67.2 billion revenue by 2030. Moreover, the rising cases of chronic diseases, such as diabetes and cardiovascular diseases (CVDs), will also propel the adoption of wearable medical devices in the upcoming years. The International Diabetes Federation (IDF) forecasts that approximately 700 million people in the 20–79 age group will be living with diabetes by 2045.

In the forthcoming years, fitness trackers will be preferred over smartwatches, smart cloths, breath analyzers, hearing aids, and patches, owing to the rising public consciousness regarding the number of steps being taken, calories being burned, and their overall health condition. All the aforementioned wearable medical devices are available at pharmacies, online platforms, and hypermarkets. In recent years, online distribution channels recorded the highest sales of these products, due to the availability of a wide range of medical devices on e-commerce platforms at cost-effective rates and the provision of home delivery services and online payment options by these portals.

These distribution channels offer wearable medical devices manufactured by Mad Apparel Inc., Xiaomi Inc., Medtronic plc, Apple Inc., Samsung Electronics Co. Ltd., ZOLL Medical Corporation, Proteus Digital Health Inc., Moov Inc., Fitbit Inc., Neurotech LLC, Senseonics Holdings Inc., Garmin Ltd., and Sony Corporation. Presently, these companies are collaborating to expand their product portfolio. For instance, in November 2019, Garmin International Inc. started collaborating with SCOR Global Life to integrate the Biological Age Model BAM solution of the latter with the wearables data offered by the former.

According to P&S Intelligence, North America led the wearable medical devices market in the preceding years, due to the presence of advanced healthcare infrastructure, high prevalence of chronic diseases, and vast geriatric population in the region. For instance, the Centers for Disease Control and Prevention (CDC) estimates that over 1.6 million people in the U.S. are diagnosed with cancer each year. Additionally, the existence of several leading wearable device manufacturers and frequent product launches are also propelling the sales of these devices in the region.

In the coming years, the Asia-Pacific (APAC) region will adopt a significant number of wearable medical devices, due to the ongoing technological developments in India, China, and Japan, surging healthcare spending, soaring cases of chronic illnesses, booming geriatric population, and mounting investments being made by public and private organizations. For example, the Government of India allocated INR 64,609 crore and INR 67,112 crore to the Ministry of Health and Family Welfare in 2019–2020 and 2020–2021, respectively.

Thus, the surging consciousness among people regarding health and fitness and increasing incidence of chronic diseases will encourage the adoption of wearable medical devices worldwide.

Pubblicato il

Biosimilars Industry Growth, Development and Future Analysis

Biosimilars Market

A number of factors such as the increasing incidence of chronic diseases, rising investments in research and development (R&D) initiatives by biopharmaceutical companies, and growing geriatric population will drive the biosimilars market at a robust CAGR, of 29.6%, during the forecast period (2019–2024). Moreover, lower price of biosimilars than reference drugs and presence of an extensive pipeline of these biological products will also catalyze the market growth. The market revenue stood at $6.0 billion in 2018 and it is projected to reach $26.7 billion by 2024.

One of the prime factors contributing to the market growth is the surging incidence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer. According to the World Health Organization (WHO), 2.26 million, 2.21 million, 1.93 million, 1.41 million, 1.20 million, and 1.09 million new cases of breast cancer, lung cancer, colon and rectum cancer, prostate cancer, skin (non-melanoma) cancer, and stomach cancer, respectively, will be recorded across the world in 2020. The WHO also estimates that approximately 17.9 million global deaths occur due to CVDs annually.

At present, companies operating in the biosimilars market are engaging in product launches to march ahead in the competition. For instance, in 2018, adalimumab was launched in the European market by Samsung Bioepis, Sandoz International GmbH, Mylan N.V., and Amgen Inc. These companies aim to launch this product in the U.S. market by 2023. Additionally, the market players are also focusing on partnerships and collaborations to consolidate their position. For example, in June 2018, Biocon India Private Limited collaborated with Sandoz International GmbH to develop, manufacture, and market next-generation biosimilars, such as Etanercept.

The product segment of the biosimilars market is classified into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides. Under this segment, the recombinant glycosylated proteins category generated the highest revenue in 2018, due to the less complexity, high stability, and smooth approval process of such biosimilars. This category is further classified into follitropin, monoclonal antibodies (mAbs), and erythropoietin (EPO). Among these, the mAbs category is expected to hold the largest market share in coming years, due to the surging usage of such biosimilars in treating cancer and diabetes.

Furthermore, the categories under the indication segment of the biosimilars market include rheumatology, oncology, infectious diseases, chronic diseases, auto-immune diseases, blood-related disorders, growth hormone deficiency (GHD), and others. Under this segment, the oncology category accounted for the largest market share in 2018, owing to the soaring cases of cancer worldwide. As per the WHO, cancer will cause approximately 10 million global deaths in 2020. The organization further estimates that lung cancer, colon and rectum cancer, and liver cancer will be the leading causes of death worldwide, accounting for 1.80 million, 935,000, and 830,000 deaths, respectively, in 2020.

According to P&S Intelligence, the European biosimilars market generated the highest revenue in 2018, due to the burgeoning aging population and mounting investments being made by the biopharmaceutical companies in R&D activities. For instance, the WHO forecasts that the number of individuals aged 85 years and over in Europe will rise from 19 million in 2020 to 40 million by 2050. Besides, the presence of a flexible regulatory framework will also fuel the demand for biosimilars in the region.

Therefore, the soaring cases of cancer and CVDs will facilitate the demand for biosimilars in the forthcoming years.

Pubblicato il

Ciao mondo!

Benvenuto in Libero Sito. Questo è un articolo di esempio per il tuo nuovo sito: puoi modificarlo o eliminarlo, aggiungere altri articoli e pagine per costruire al meglio il tuo Libero Sito